ASPIRE BIOPHARMA HLDGS INC
COM · CUSIP 738920206
0
institutional holders
-13 vs Q1 2026
—reported value*
0 new
0 added
0 reduced
13 sold out
net sold ≈ $363.5k (-353.3k shares)
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable.
Trends to Q2 2026
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q1 2026 | 13 |
| Q2 2026 | 0 |
Biggest buyers
| None |
Biggest sellers
| UBS Group AG | Sold out | -191.5k |
| MORGAN STANLEY | Sold out | -77.0k |
| GEODE CAPITAL MANAGEMENT, LLC | Sold out | -43.4k |
| Crewe Advisors LLC | Sold out | -20.3k |
| VANGUARD CAPITAL MANAGEMENT LLC | Sold out | -7.9k |
| TORONTO DOMINION BANK | Sold out | -5.0k |
| VANGUARD FIDUCIARY TRUST CO | Sold out | -2.9k |
| Tower Research Capital LLC (TRC) | Sold out | -2.2k |
| CITIGROUP INC | Sold out | -1.8k |
| Avion Wealth | Sold out | -1.4k |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
| HIGHBRIDGE CAPITAL MANAGEMENT LLC 13G · institution new · filed 2026-05-15 | 5.2% |
Holders, Q2 2026
| Manager | Shares | Change |
|---|